Amyris, Inc. (NASDAQ:AMRS) is set to announce its earnings results after the market closes on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.77) per share for the quarter.
Amyris (NASDAQ:AMRS) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.06) by ($0.35). The company had revenue of $25.68 million during the quarter, compared to analysts’ expectations of $23.68 million. During the same quarter in the prior year, the firm earned ($0.06) EPS. The company’s revenue was up 167.5% compared to the same quarter last year. On average, analysts expect Amyris to post $-3.32 EPS for the current fiscal year and $-1.84 EPS for the next fiscal year.
COPYRIGHT VIOLATION NOTICE: “Amyris, Inc. (AMRS) Set to Announce Quarterly Earnings on Wednesday” was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.com-unik.info/2017/11/01/amyris-inc-amrs-set-to-announce-quarterly-earnings-on-wednesday.html.
Several equities analysts have recently commented on AMRS shares. Zacks Investment Research upgraded shares of Amyris from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a report on Wednesday, October 4th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Amyris in a report on Tuesday, September 26th. Cowen and Company set a $4.00 price target on shares of Amyris and gave the company a “hold” rating in a report on Thursday, August 17th. Finally, ValuEngine upgraded shares of Amyris from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. Amyris presently has an average rating of “Hold” and a consensus price target of $20.69.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
What are top analysts saying about Amyris Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amyris Inc. and related companies.